I

    Inhibikase Therapeutics Inc (IKT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.31
    -0.10 (-4.15%)

    Market Cap: $336.28M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    48%(10/21)
    Avg Surprise
    -10.19%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.10
    Range$-0.11 - $-0.09
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.10-3.4%
    60d ago$-0.10-3.4%
    30d ago$-0.09+6.9%
    7d ago$-0.09+6.9%
    Current$-0.10
    Revenue Consensus
    $0
    Range$0 - $0
    6 analysts
    Dec 31, 2026
    EPS Consensus$-0.17
    Range$-0.17 - $-0.16
    2 analysts
    Revenue Consensus
    $214290
    Range$0 - $2M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.17---
    Sep 26EST
    		-$-0.10---
    Jun 26
    		$-0.11$-0.09-22.22%Miss+0.0%
    Mar 26
    		$-0.10$-0.09-5.67%Miss+36.6%
    Dec 25
    		$-0.09$-0.12+25.00%Beat+48.5%
    Sep 25
    		$-0.13$-0.13+0.00%Beat+80.0%
    Jun 25
    		$-0.11$-0.08-37.50%Miss+83.3%
    Mar 25
    		$-0.15$-0.09-66.67%Miss+79.5%
    Dec 24
    		$-0.17$-0.09-101.73%Miss+72.7%
    Sep 24
    		$-0.65$-0.48-35.42%Miss+24.4%
    Jun 24
    		$-0.66$-0.67+1.49%Beat+40.5%
    Mar 24
    		$-0.73$-0.79+7.59%Beat+24.0%
    Dec 23
    		$-0.64$-0.85+24.71%Beat-255.6%
    Sep 23
    		$-0.86$-1.12+23.21%Beat-377.8%
    Jun 23
    		$-1.11$-0.92-20.65%Miss-516.7%
    Mar 23
    		$-0.96$-0.90-6.67%Miss-433.3%
    Dec 22
    		$-0.18$-0.19+5.26%Beat+10.0%
    Sep 22
    		$-0.18$-0.18+0.00%Beat+0.0%
    Jun 22
    		$-0.18$-0.19+5.26%Beat+18.2%
    Mar 22
    		$-0.18$-0.17-5.88%Miss+30.8%
    Dec 21
    		$-0.20$-0.17-17.65%Miss-33.3%
    Sep 21
    		$-0.18$-0.14-28.57%Miss-125.0%
    Jun 21
    		$-0.22$-0.38+42.11%Beat-266.7%
    Mar 21
    		$-0.26N/AN/ABeat-403.9%
    Dec 20
    		$-0.15N/AN/ABeat-124.2%
    Sep 20
    		$-0.08$0.00N/AMiss-52.1%
    Jun 20
    		$-0.06$0.00N/AMiss+59.5%
    Mar 20
    		$-0.05$0.00N/AMiss+82.0%
    Dec 19
    		$-0.07$0.00N/AMiss+68.5%
    Sep 19
    		$-0.05$0.00N/AMiss+47.4%
    Jun 19
    		$-0.15$0.00N/AMiss-826.2%
    Mar 19
    		$-0.29$0.00N/AMiss-1103.8%
    Dec 18
    		$-0.21$0.00N/AMiss-
    Sep 18
    		$-0.10$0.00N/AMiss-
    Dec 17
    		$-0.02$0.00N/AMiss-
    Dec 16
    		$-0.02$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-5.43EV/EBITDA0.34x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-52.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage13.63x
    Current Ratio15.82xQuick Ratio15.82x
    Trading Statistics
    Beta0.95Avg Volume486.07K
    52-Week High$2.5452-Week Low$1.33

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.43
    SMA 20$2.43
    SMA 50$2.22
    SMA 200$1.86
    EMA 10$2.42
    EMA 20$2.39
    EMA 50$2.24
    EMA 200$1.96

    MACD

    Line: 0.05Signal: 0.08Hist: -0.02

    ADX

    ADX: 31.7+DI: 19.6-DI: 19.6

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down16.0
    PSAR$2.54

    Bollinger Bands

    Upper Band$2.52
    Lower Band$2.33
    %B Position814%(Upper)
    Band Width-0.09

    RSI (14-Day)

    Neutral
    46.5

    Momentum Oscillators

    Stoch %K39.1
    Stoch %D59.9
    Williams %R-95.8
    ROC (10d)-3.3%
    Momentum-0.08
    CCI (20d)-140.6
    MFI (14d)43.8

    Volatility Measures

    ATR (14d)$0.12(5.2%)
    StdDev (20d)0.05
    Hist Vol50.3%(High)

    Volume Flow

    VWAP$2.35
    OBV25.8M
    AD Line-40.3M
    CMF (20d)0.062

    Volume Metrics

    Avg Vol (20d)486.0K
    Vol Ratio0.7x
    VWMA (20d)$2.43

    Pivot Points

    R3$2.58
    R2$2.53
    R1$2.47
    Pivot Point$2.42
    S1$2.36
    S2$2.31
    S3$2.25

    Advanced Oscillators

    TSI16.70
    Ultimate Osc52.9
    KST107.86

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$26,274$0$0$0$-195,979$79,569
    Cost of Revenue$0$0$36,811$0$0$0$6,567$0$0$0$6,568$0
    Gross Profit$0$0$-36,811$0$0$0$-6,567$0$0$0$-195,979$79,569
    Operating Expenses$21.05M$17.84M$13.78M$12.77M$10.83M$14.60M$12.93M$5.83M$5.05M$4.78M$4.21M$4.85M
    R&D$13.39M$10.84M$6.36M$7.65M$5.27M$10.51M$7.19M$4.19M$3.08M$2.75M$3.00M$3.23M
    SG&A$7.66M$7.38M$6.77M$5.61M$5.92M$5.25M$5.74M$1.64M$1.97M$2.03M$1.40M$1.62M
    Operating Income$-21,050,995$-17,841,919$-13,775,626$-12,768,373$-10,832,278$-14,598,006$-12,928,697$-5,827,476$-5,050,535$-4,782,360$-4,403,566$-4,768,876
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$-1,459,764$-1,461,079$-1,040,975$-838,093$-916,755$-919,271$-796,120$-49,410$-90,927$-132,725$-225,626$-173,677
    Income Before Tax$-19,591,231$-16,380,840$-12,770,932$-11,930,280$-9,917,500$-13,678,735$-12,168,025$-5,778,066$-4,959,608$-4,652,312$-4,011,975$-4,593,628
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-19,591,231$-16,380,840$-12,734,651$-11,930,280$-9,915,523$-13,678,735$-12,132,577$-5,778,066$-4,959,608$-4,649,635$-4,177,940$-4,595,199
    EBITDA$-21,050,995$-17,841,919$-13,775,626$-12,744,686$-10,810,097$-14,585,352$-12,922,130$-5,820,908$-5,043,966$-4,778,469$-4,396,998$-4,760,722
    EBIT$-21,050,995$-17,841,919$-13,775,626$-12,768,373$-10,834,255$-14,598,006$-12,928,697$-5,827,476$-5,050,535$-4,785,037$-4,403,566$-4,767,305
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IKT

    News

    Perceptive group (IKT) discloses 6.9% Inhibikase stake through 10.3M warrant shares

    Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have disclosed a beneficial ownership of 6.9% in Inhibikase Therapeutics, Inc. (IKT) through warrants. This stake, totaling 10,320,875 shares, is primarily held by the Master Fund through various pre-funded and common warrants, subject to a 9.99% beneficial ownership limitation. Perceptive Advisors acts as the investment manager for the Master Fund, and Joseph Edelman is its managing member.

    Stock Titan•8/14/26•
    Neutral

    Nantahala reports 4.30% Inhibikase (IKT) stake across 5.81M shares

    Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 4.30% in Inhibikase Therapeutics (IKT), totaling 5,810,487 shares as of June 30, 2026. This stake includes 3,108,624 shares acquirable through convertible securities within sixty days. The reporting persons share voting and dispositive power over these shares, indicating ownership of five percent or less of the class.

    Stock Titan•8/14/26•
    Neutral

    Sands Capital group (NASDAQ: IKT) discloses 9.3% Inhibikase stake plus large warrants

    Sands Capital Life Sciences Pulse Fund II, L.P., along with related entities, has reported a beneficial ownership of 9.3% in Inhibikase Therapeutics, Inc. This stake includes 13,018,965 shares of common stock and substantial warrants for an additional 15.5 million shares, although these warrants are not included in the current ownership percentage due to exercise restrictions. The filing indicates shared voting and dispositive power among the reporting persons, with a beneficial ownership limitation of 19.99% on the warrants.

    Stock Titan•8/13/26•
    Neutral

    Oppenheimer Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5

    Oppenheimer has reiterated its Buy rating on Inhibikase Therapeutics (IKT.US), maintaining a target price of $5. This indicates continued confidence from the firm in the company's prospects.

    Moomoo•8/13/26•
    Bullish

    Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

    Inhibikase Therapeutics announced its Q2 2026 financial results, reporting a net loss of $19.6 million and $159.0 million in cash and marketable securities. The company highlighted significant progress in its Phase 3 IMPROVE-PAH study for IKT-001, including regulatory approvals in 26 countries and recent site initiations. Additionally, Inhibikase secured $50 million from RA Capital Management and received Orphan Drug Designation for IKT-001 from the U.S. FDA, strengthening its position to advance the drug.

    GlobeNewswire•8/12/26•
    Bullish

    Frequently Asked Questions About IKT

    Does IKT pay dividends?
    Inhibikase Therapeutics Inc (IKT) does not currently pay a regular dividend.
    What is IKT's market cap?
    Inhibikase Therapeutics Inc (IKT) has a market capitalization of $336.28M with a current stock price of $2.31.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In